Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Hepatitis C, Chronic 1Carcinoma, Hepatocellular 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3Radiotherapy 3Propranolol 3Cisplatin 3entecavir 2Tranexamic Acid 2Pemetrexed 2Metformin 2Erythromycin 2Epinephrine 2Cyclophosphamide 2Chemoradiotherapy 2Bortezomib 2ulipristal acetate 1tislelizumab 1plerixafor 1lobaplatin 1ledipasvir 1eribulin 1endostar protein 1dolutegravir 1colistinmethanesulfonic acid 1cetrorelix 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1XELOX 1Vancomycin 1Vacuum Curettage 1Vaccination 1Suction 1Sofosbuvir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × OTHER_GOV × ledipasvir × Clear all
NCT02959359 2017-08-07

DAA in the Risk of Recurrence After Curative Treatment of HCC

Taipei Veterans General Hospital, Taiwan

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡